The field just got its driver’s licence
Dane Gobel runs the Methuselah Foundation’s prize competitions — including a partnership with NASA — and works with the Biomarker of Aging Consortium, part of the group behind the Biomarkers of Aging conference at Harvard. He is also Dave Gobel’s son, which means he has spent most of his life inside a field that spent most of its life being laughed at.
That gives him an unusually long view. His verdict is that longevity research no longer feels like something gestating — it feels like something that has finally been born. His analogy is a teenager who has just passed their driving test: not yet an apartment in the city, but genuinely able to navigate the world.
He is careful about the framing everyone else fights over. He does not think aging is a disease. He thinks it is a hundred or more different things that can go wrong, conveniently bundled under one label — and that treating the label as a single target has been useful politically while remaining scientifically misleading.
He is also honest about where progress actually came from. The first ten years were brutal, though oddly low-risk, since everyone already assumed you were insane and any ground gained counted as a win. Regenerative medicine and 3D bioprinting made the field legible around 2010, because nobody objects to growing spare organs. The first gerotherapeutic startups followed in 2015 and 2016, and are only now reaching trials. And the first drug that genuinely moves healthspan at scale, he suspects, is a GLP-1 — which came from outside the longevity world entirely.
